Photo of Robert L. Martuza,  MD

Robert L. Martuza, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 726-8583
Fax: (617) 726-4814


rmartuza@partners.org

Robert L. Martuza, MD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • William and Elizabeth Sweet Professor of Neuroscience in the Department of Neurosurgery, Neurosurgery, Harvard Medical School
  • Chief, Neurosurgery, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Publications

Powered by Harvard Catalyst
  • Nigim F, Esaki SI, Hood M, Lelic N, James MF, Ramesh V, Stemmer-Rachamimov A, Cahill DP, Brastianos PK, Rabkin SD, Martuza RL, Wakimoto H. A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus. 2016. PubMed
  • Hwang WL, Marciscano AE, Niemierko A, Kim DW, Stemmer-Rachamimov AO, Curry WT, Barker FG, Martuza RL, Loeffler JS, Oh KS, Shih HA, Larvie M. Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade. 2015. PubMed
  • Marciscano AE, Stemmer-Rachamimov AO, Niemierko A, Larvie M, Curry WT, Barker FG, Martuza RL, McGuone D, Oh KS, Loeffler JS, Shih HA. Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes. J Neurosurg 2015. PubMed
  • Nigim F, Cavanaugh J, Patel AP, Curry WT, Esaki S, Kasper EM, Chi AS, Louis DN, Martuza RL, Rabkin SD, Wakimoto H. Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment. J Neuropathol Exp Neurol 2015; 74:710-22. PubMed
  • Lu L, Saha D, Martuza RL, Rabkin SD, Wakimoto H. Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma. J. Neurooncol. 2015. PubMed
  • Antoszczyk S, Spyra M, Mautner VF, Kurtz A, Stemmer-Rachamimov AO, Martuza RL, Rabkin SD. Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus. 2014. PubMed
  • Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, Louis DN, Rozenblatt-Rosen O, Suvà ML, Regev A, Bernstein BE. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014. PubMed
  • Suvà ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD, Riggi N, Chi AS, Cahill DP, Nahed BV, Curry WT, Martuza RL, Rivera MN, Rossetti N, Kasif S, Beik S, Kadri S, Tirosh I, Wortman I, Shalek AK, Rozenblatt-Rosen O, Regev A, Louis DN, Bernstein BE. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell 2014; 157:580-94. PubMed
  • Sheth SA, Tirino JL, Martuza RL. Vestibular schwannoma: suboccipital approach. Neurosurg Focus 2014; 36:1. PubMed
  • Cheema TA, Wakimoto H, Fecci PE, Ning J, Kuroda T, Jeyaretna DS, Martuza RL, Rabkin SD. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci U S A 2013; 110:12006-11. PubMed
  • Zhang W, Fulci G, Wakimoto H, Cheema TA, Buhrman JS, Jeyaretna DS, Stemmer Rachamimov AO, Rabkin SD, Martuza RL. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. Neoplasia 2013; 15:591-9. PubMed
  • Rheinbay E, Suvà ML, Gillespie SM, Wakimoto H, Patel AP, Shahid M, Oksuz O, Rabkin SD, Martuza RL, Rivera MN, Louis DN, Kasif S, Chi AS, Bernstein BE. An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep 2013; 3:1567-79. PubMed
  • Las Heras F, Martuza R, Caruso P, Rincon S, Stemmer-Rachamimov A. 24-year-old woman with an internal auditory canal mass. Hybrid peripheral nerve sheath tumor with schwannoma/perineurioma components. Brain Pathol 2013; 23:361-2. PubMed
  • Tamura K, Wakimoto H, Agarwal AS, Rabkin SD, Bhere D, Martuza RL, Kuroda T, Kasmieh R, Shah K. Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors. Mol Ther 2013; 21:68-77. PubMed
  • Ginat DT, Martuza RL. Postoperative imaging of vestibular schwannomas. Neurosurg Focus 2012; 33:E18. PubMed
  • Barnard Z, Wakimoto H, Zaupa C, Patel AP, Klehm J, Martuza RL, Rabkin SD, Curry WT. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma. Neurosurgery 2012; 71:741-8; discussion 748. PubMed
  • Sgubin D, Wakimoto H, Kanai R, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells. Stem Cells Transl Med 2012; 1:322-32. PubMed
  • Peterfreund RA, Luman E, Martuza RL. Anesthesia for suboccipital craniotomy in a patient with lymphangioleiomyomatosis: a case report. Case Rep Pulmonol 2012; 2012:804789. PubMed
  • Elstner A, Stockhammer F, Nguyen-Dobinsky TN, Nguyen QL, Pilgermann I, Gill A, Guhr A, Zhang T, von Eckardstein K, Picht T, Veelken J, Martuza RL, von Deimling A, Kurtz A. Identification of diagnostic serum protein profiles of glioblastoma patients. J. Neurooncol. 2010. PubMed
  • Castelo-Branco P, Passer BJ, Buhrman JS, Antoszczyk S, Marinelli M, Zaupa C, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer. Gene Ther 2010; 17:805-10. PubMed
  • Passer BJ, Cheema T, Zhou B, Wakimoto H, Zaupa C, Razmjoo M, Sarte J, Wu S, Wu CL, Noah JW, Li Q, Buolamwini JK, Yen Y, Rabkin SD, Martuza RL. Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Res 2010; 70:3890-5. PubMed
  • Stankovic KM, Mrugala MM, Martuza RL, Silver M, Betensky RA, Nadol JB, Stemmer-Rachamimov AO. Genetic determinants of hearing loss associated with vestibular schwannomas. Otol. Neurotol. 2009; 30:661-7. PubMed
  • Passer BJ, Castelo-Branco P, Buhrman JS, Varghese S, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells. Cancer Gene Ther 2009; 16:551-60. PubMed
  • Wakimoto H,Kesari S,Farrell CJ,Curry WT Jr,Zaupa C,Aghi M,Kuroda T,Stemmer-Rachamimov A,Shah K,Liu TC,Jeyaretna DS,Debasitis J,Pruszak J,Martuza RL,Rabkin SD. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 2009; 69:3472-81. PubMed
  • Sasportas LS,Kasmieh R,Wakimoto H,Hingtgen S,van de Water JA,Mohapatra G,Figueiredo JL,Martuza RL,Weissleder R,Shah K. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A 2009; 106:4822-7. PubMed
  • Aghi MK,Liu TC,Rabkin S,Martuza RL. Hypoxia enhances the replication of oncolytic herpes simplex virus. Mol Ther 2008; 17:51-6. PubMed
  • Aghi MK,Carter BS,Cosgrove GR,Ojemann RG,Amin-Hanjani S,Martuza RL,Curry WT Jr,Barker FG 2nd. Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 2009; 64:56-60; discussion 60. PubMed
  • Farrell CJ,Zaupa C,Barnard Z,Maley J,Martuza RL,Rabkin SD,Curry WT Jr. Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells. Clin Cancer Res 2008; 14:7711-6. PubMed
  • Farassati F,Pan W,Yamoutpour F,Henke S,Piedra M,Frahm S,Al-Tawil S,Mangrum WI,Parada LF,Rabkin SD,Martuza RL,Kurtz A. Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes. Am J Pathol 2008; 173:1861-72. PubMed
  • Liu TC, Castelo-Branco P, Rabkin SD, Martuza RL. Trichostatin A and Oncolytic HSV Combination Therapy Shows Enhanced Antitumoral and Antiangiogenic Effects. Mol Ther 2008; 16:1041-7. PubMed
  • Sher DJ, Henson JW, Avutu B, Hochberg FH, Batchelor TT, Martuza RL, Barker FG 2nd, Loeffler JS, Chakravarti A. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. J Neurooncol 2008; 88:43-50. PubMed
  • Liu TC, Wakimoto H, Martuza RL, Rabkin SD. Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics. Clin Cancer Res 2007; 13:5897-902. PubMed
  • Fulci G, Dmitrieva N, Gianni D, Fontana EJ, Pan X, Lu Y, Kaufman CS, Kaur B, Lawler SE, Lee RJ, Marsh CB, Brat DJ, van Rooijen N, Stemmer-Rachamimov AO, Hochberg FH, Weissleder R, Martuza RL, Chiocca EA. Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res 2007; 67:9398-406. PubMed
  • Varghese S, Rabkin SD, Nielsen GP, MacGarvey U, Liu R, Martuza RL. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res 2007; 67:9371-9. PubMed
  • Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, Liu TC, Rabkin S, Martuza R, Breakefield XO. Treatment of Implantable NF2 Schwannoma Tumor Models with Oncolytic Herpes Simplex Virus G47Delta. Cancer Gene Ther 2007; 14:460-7. PubMed
  • Aghi M, Rabkin SD, Martuza RL. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res 2007; 67:440-4. PubMed
  • Jeyaretna DS, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus therapy for peripheral nerve tumors. Neurosurg Focus 2007; 22:E4. PubMed
  • Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Martuza RL, Rabkin SD, Kurtz A. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther 2006; 14:789-97. PubMed
  • Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X, Bikfalvi A, Martuza RL, Kurtz A, Rabkin SD. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res 2006; 12:6791-9. PubMed
  • Kuroda T, Rabkin SD, Martuza RL. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. Cancer Res 2006; 66:10127-35. PubMed
  • Martuza RL. Vestibular schwannoma. J Neurosurg 2006; 105:526; discussion 526. PubMed
  • Varghese S, Rabkin SD, Nielsen PG, Wang W, Martuza RL. Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clin Cancer Res 2006; 12:2919-27. PubMed
  • Aghi M, Rabkin S, Martuza RL. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst 2006; 98:38-50. PubMed
  • Kuroda T, Martuza RL, Todo T, Rabkin SD. Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases. BMC Biotechnol 2006; 6:40. PubMed
  • Messerli SM, Prabhakar S, Tang Y, Mahmood U, Weissleder R, Bronson R, Martuza R, Rabkin S, Breakefield XO. Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. Hum Gene Ther 2006; 17:20-30. PubMed
  • Aghi M, Rabkin S, Martuza RL. Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair. Clin Neurosurg 2007; 53:65-76. PubMed
  • Castelo-Branco P, Passer BJ, Buhrman JS, Antoszczyk S, Marinelli M, Zaupa C, Rabkin SD, Martuza . An oncolytic herpes simplex virus armed with a xenogeneic homologue of prostatic acid phosphatase enhances anti-tumor efficacy in prostate cancer Gene Ther 2010.
Hide